The spectrum of antidiabetic actions of GLP-1 in patients with diabetes

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 4, 2009, Pages 453-462

  Vilsbøll, Tina ^a   Holst, Jens J ^a   Knop, Filip K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

antidiabetic; beta cell function; glucagon; glucagon like peptide 1 (GLP 1); incretin hormones; type 2 diabetes mellitus

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ALPHA GLUCOSIDASE INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; INSULIN DERIVATIVE; LIRAGLUTIDE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

APPETITE; DOSE RESPONSE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN;

APPETITE; DIABETES MELLITUS, TYPE 2; EATING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS;

EID: 69849083556     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.03.011     Document Type: Review

References (95)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Roglic G., Unwin N., Bennett P.H., et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28 (2005) 2130-2135
3. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
4. Gaede P., Valentine W.J., Palmer A.J., et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes - Results and projections from the Steno-2 study. Diabetes Care 31 (2008) 1510-1515
5. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine 359 (2008) 1577-1589
6. Chalmers J., and Cooper M.E. UKPDS and the legacy effect. The New England Journal of Medicine 359 (2008) 1618-1620
7. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52 (2009) 17-30
8. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 147 (2007) 386-399
9. Maedler K., Carr R.D., Bosco D., et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 501-506
10. Holst J.J. The physiology of glucagon-like peptide 1. Physiological Reviews 87 (2007) 1409-1439
11. Holz G.G. Epac: a new cAMP-binding protein in support of Glucagon-Like Peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53 (2004) 5-13
12. Doyle M.E., and Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology and Therapeutics 113 (2007) 546-593
13. Tsuboi T., da Silva Xavier G., Holz G.G., et al. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochemical Journal 369 (2003) 287-299
14. de Heer, J. and Holst, J.J. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438-443.
15. Wang Y., Egan J.M., Raygada M., et al. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 136 (1995) 4910-4917
16. Kemp D.M., and Habener J.F. Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology 142 (2001) 1179-1187
17. Lawrence M.C., Bhatt H.S., and Easom R.A. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes 51 (2002) 691-698
18. Li Y., Cao X., Li L.X., et al. Beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 (2005) 482-491
19. Klinger S., Poussin C., Debril M.B., et al. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes 57 (2008) 584-593
20. Buteau J., Roduit R., Susini S., et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. [In Process Citation]. Diabetologia 42 (1999) 856-864
21. Holz G.H., Kuhtreiber W.M., and Habener J.F. Induction of glucose competence in pancreatic beta cells by glucagon- like peptide-1(7-37). Transactions of the Association of American Physicians 105 (1992) 260-267
22. Gromada J., Holst J.J., and Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Archiv 435 (1998) 583-594
23. Flamez D., Van Breusegem A., Scrocchi L.A., et al. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes 47 (1998) 646-652
24. Bonner-Weir S. Beta-cell turnover: its assessment and implications. Diabetes 50 Suppl. 1 (2001) S20-S24
25. Egan J.M., Bulotta A., Hui H., et al. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes/Metabolism Research and Reviews 19 (2003) 115-123
26. Farilla L., Hui H., Bertolotto C., et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
27. Zhou J., Wang X., Pineyro M.A., et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42 J cells into glucagon- and insulin-producing cells. Diabetes 48 (1999) 2358-2366
28. Farilla L., Bulotta A., Hirshberg B., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
29. Drucker D.J. The biology of incretin hormones. Cell Metabolism 3 (2006) 153-165
30. Orskov C., Holst J.J., and Nielsen O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123 (1988) 2009-2013
31. Toft-Nielsen M.B., Damholt M.B., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. The Journal of Clinical Endocrinology Metabolism 86 (2001) 3717-3723
32. Shah P., Vella A., Basu A., et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. The Journal of Clinical Endocrinology Metabolism 85 (2000) 4053-4059
33. Creutzfeldt W.O., Kleine N., Willms B., et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19 (1996) 580-586
34. de Heer J., Hoy M., and Holst J.J. GLP-1, but not GIP, inhibits glucagon secretion via somatostatin in the perfused rat pancreas. [Abstract]. Diabetologia 48 Suppl. 1 (2005)
35. Fehmann H.C., Goke R., and Goke B. Cell and molecular biology of the incretin hormones glucagon- like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews 16 (1995) 390-410
36. Heller R.S., Kieffer T.J., and Habener J.F. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46 (1997) 785-791
37. Moens K., Heimberg H., Flamez D., et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45 (1996) 257-261
38. Tornehave D., Kristensen P., Romer J., et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. The Journal of Histochemistry and Cytochemistry 56 (2008) 841-851
39. Ding W.G., Renstrom E., Rorsman P., et al. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46 (1997) 792-800
40. Nauck M.A., Heimesaat M.M., Behle K., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of Clinical Endocrinology Metabolism 87 (2002) 1239-1246
41. Wettergren A., Schjoldager B., Mortensen P.E., et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Digestive Diseases and Sciences 38 (1993) 665-673
42. Nauck M.A., Niedereichholz U., Ettler R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology 273 (1997) E981-E988
43. Layer P., Holst J.J., Grandt D., et al. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Digestive Diseases and Sciences 40 (1995) 1074-1082
44. Schjoldager B.T., Mortensen P.E., Christiansen J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Digestive Diseases and Sciences 34 (1989) 703-708
45. Groger G., Unger A., Holst J.J., et al. Ileal carbohydrates inhibit cholinergically stimulated exocrine pancreatic secretion in humans. International Journal of Pancreatology 22 (1997) 23-29
46. Wettergren A., Maina P., Boesby S., et al. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man. Scandinavian Journal of Gastroenterology 32 (1997) 552-555
47. Read N., French S., and Cunningham K. The role of the gut in regulation food intake in man. Nutrition Reviews 52 (1994) 1-10
48. Holst J.J. Enteroglucagon. Annual Review of Physiology 59 (1997) 257-271
49. Layer P. Intestinal regulation of pancreatic enzyme secretion: stimulatory and inhibitory mechanisms. Intestinale Regulation der Pankreasenzymsekretion: Stimulatorische und inhibitorische Mechanismen. Z Gastroenterology 30 (1992) 495-497
50. Wettergren A., Petersen H., Orskov C., et al. Glucagon-like peptide-1 7-36 amide and peptide YY from the L- cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scandinavian Journal of Gastroenterology 29 (1994) 501-505
51. Wettergren A., Wojdemann M., Meisner S., et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40 (1997) 597-601
52. Schirra J., Nicolaus M., Roggel R., et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55 (2006) 243-251
53. Vilsboll T., Agerso H., Krarup T., et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. The Journal of Clinical Endocrinology Metabolism 88 (2003) 220-224
54. Hansen L., Deacon C.F., Orskov C., et al. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. [In Process Citation]. Endocrinology 140 (1999) 5356-5363
55. Holst J.J., and Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48 (2005) 612-615
56. Nishizawa M., Nakabayashi H., Uchida K., et al. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. Journal of the Autonomic Nervous System 61 (1996) 149-154
57. Nakabayashi H., Nishizawa M., Nakagawa A., et al. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. American Journal of Physiology 271 (1996) E808-E813
58. Karlsson S., Scheurink A.J., Steffens A.B., et al. Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice. American Journal of Physiology 267 (1994) R1071-R1077
59. Vilsboll T., Krarup T., Sonne J., et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. The Journal of Clinical Endocrinology Metabolism 88 (2003) 2706-2713
60. Holst J.J. Glucagon-like Peptide 1(GLP-1): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential. Trends in Endocrinology and Metabolism 10 (1999) 229-234
61. Imeryuz N., Yegen B.C., Bozkurt A., et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms. American Journal of Physiology 273 (1997) G920-G927
62. Wettergren A., Wojdemann M., and Holst J.J. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. American Journal of Physiology 275 (1998) G984-G992
63. Holst J.J., Rasmussen T.N., Harling H., et al. Effect of intestinal inhibitory peptides on vagally induced secretion from isolated perfused porcine pancreas. Pancreas 8 (1993) 80-87
64. Burcelin R., Da Costa A., Drucker D., et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50 (2001) 1720-1728
65. Ionut V., Liberty I.F., Hucking K., et al. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. American Journal of Physiology Endocrinology and Metabolism 291 (2006) E779-E785
66. Kreymann B., Williams G., Ghatei M.A., et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
67. Hvidberg A., Nielsen M.T., Hilsted J., et al. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolismo 43 (1994) 104-108
68. Jin S.L., Han V.K., Simmons J.G., et al. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. The Journal of Comparative Neurology 271 (1988) 519-532
69. Schick R.R., vorm Walde T., Zimmermann J.P., et al. Glucagon-like peptide 1-a novel brain peptide involved in feeding regulation. In: Ditschuneit H., Gries F.A., Hauner H., et al. (Eds). Obesity in Europe 1993 (1994), John Libbey & Co.Ltd 363-367
70. Tang-Christensen M., Larsen P.J., Goke R., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. American Journal of Physiology 271 (1996) R848-R856
71. Turton M.D., O'Shea D., Gunn I., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. [see comments]. Nature 379 (1996) 69-72
72. Tang-Christensen M., Vrang N., and Larsen P.J. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47 (1998) 530-537
73. Dakin C.L., Gunn I., Small C.J., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142 (2001) 4244-4250
74. Tang-Christensen M., Larsen P.J., Thulesen J., et al. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. [In Process Citation]. Natural Medicines 6 (2000) 802-807
75. Flint A., Raben A., Astrup A., et al. Glucagon-like Peptide 1 promotes satiety and suppresses energy intake in humans. The Journal of Clinical Investigation 101 (1998) 515-520
76. Verdich C., Flint A., Gutzwiller J.P., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. The Journal of Clinical Endocrinology Metabolism 86 (2001) 4382-4389
77. Naslund E., Barkeling B., King N., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. International Journal of Obesity Related Metabolic Disorders 23 (1999) 304-311
78. Gutzwiller J.P., Drewe J., Goke B., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. American Journal of Physiology 276 (1999) R1541-R1544
79. Zander M., Madsbad S., Madsen J.L., et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
80. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372 (2008) 1240-1250
81. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009) 473-481
82. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 24 (2008) 275-286
83. Nauck M.A., Duran S., Kim D., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50 (2007) 259-267
84. Orskov C., Poulsen S.S., Moller M., et al. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45 (1996) 832-835
85. Nauck M.A., Kleine N., Orskov C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon- like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
86. D'Alessio D.A., Kahn S.E., Leusner C.R., et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin- independent glucose disposal. The Journal of Clinical Investigation 93 (1994) 2263-2266
87. Toft-Nielsen M., Madsbad S., and Holst J.J. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45 (1996) 552-556
88. Orskov L., Holst J.J., Moller J., et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39 (1996) 1227-1232
89. Vella A., Shah P., Reed A.S., et al. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45 (2002) 1410-1415
90. Ahren B., Larsson H., and Holst J.J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology Metabolism 82 (1997) 473-478
91. Vella A., Shah P., Basu R., et al. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49 (2000) 611-617
92. Meneilly G.S., Greig N., Tildesley H., et al. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26 (2003) 2835-2841
93. Nishizawa M., Moore M.C., Shiota M., et al. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. American Journal of Physiology Endocrinology and Metabolism 284 (2003) E1027-E1036
94. Dardevet D., Moore M.C., Neal D., et al. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. American Journal of Physiology Endocrinology and Metabolism 287 (2004) E75-E81
95. Ionut V., Hucking K., Liberty I.F., et al. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48 (2005) 967-975